SNNC 10-Q Quarterly Report May 31, 2013 | Alphaminr
Sibannac, Inc.

SNNC 10-Q Quarter ended May 31, 2013

10-Q 1 naprodis10q053113.htm NAPRODIS 10Q, 05.31.13 naprodis10q053113.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
(Mark One)

x
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934

For the quarterly period ended May 31, 2013

o
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ______________

Commission File Number: 333-122009
NAPRODIS, INC.
(Exact Name of Registrant as Specified in its Charter)

Nevada
33-0903494
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

13250 Gregg St., Suite F, Poway, CA 92064
(Address of Principal Executive Offices)  (Zip Code)

Registrant's telephone number including area code: (858) 486-8655

N/A
Former name, former address, and former fiscal year, if changed since last report

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes o No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Larger accelerated filer
o
Accelerated filer
o
Non-accelerated filer
o
Smaller reporting company
x

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 4,990,000 shares outstanding as of  July 15, 2013.

PART I

Item 1.  Financial Statements




NAPRODIS, INC.

FINANCIAL STATEMENTS

For the nine months ended

May 31, 2013






FINANCIAL ST ATEMENTS



NAPRO DI S, INC.
BALANCE SHEETS
(Unaudited)
May 31,
August 31,
2013
2012
ASSETS
Current Assets
Cash
$ 11,102 $ 648
Accounts Receivable
27,713 11,396
Inventories, net
112,317 118,083
Total Current Assets
151,132 130,127
Property and equipment, net
30,218 40,523
Other Assets
10,159 10,159
TOTAL ASSETS
$ 191,509 $ 180,809
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts Payable and accrued expenses
$ 153,975 $ 98,021
Accrued payroll and payroll taxes
1,535 1,484
Accrued Interest
41,262 33,795
Customer Deposits
7,335 -
Payables to related party
124,101 124,523
Officer Loans
209,914 206,542
Total Liabilities
538,122 464,365
Stockholders' Deficit
Preferred stock, $0.001 par value,
10,000,000 shares authorized, 0 shares issued
- -
Common Stock, $0.001 par value,
60,000,000 shares authorized;
4,990,000 isssued and outstanding at
May 31, 2013 and August 31, 2012
4,990 4,990
Additional paid-in capital
131,260 131,260
Deficit
(482,863 ) (419,806 )
Total Stockholders's Deficit
(346,613 ) (283,556 )
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
$ 191,509 $ 180,809
The accompanying notes are an integral part of these unaudited financial statements
NAPRODIS, I NC.
STATEMENTS OF OPERATIONS
(Unaudited)
For the Three Months Ended
For the Nine Months Ended
May 31,
May 31,
2013
2012
2013
2012
Revenues
$ 37,913 $ 46,521 $ 156,414 $ 278,380
Cost of sales, (exclusive of depreciation,
included in general & administrative expenses)
15,238 6,695 29,911 18,623
Gross Profit 22,675 39,826 126,503 259,757
Selling, General and Administrative Expenses
Selling Expenses 246 5,184 6,828 11,533
Occupancy costs
33,880 31,625 100,492 95,654
Salaries and wages
2,802 2,746 7,145 86,350
Freight
2,819 2,095 5,906 24,195
Legal and Professional fees
3,000 500 16,108 500
Other general and administrative
Expenses
8,620 16,907 43,556 106,104
Total selling, general and administrative expenses
51,367 59,057 180,035 324,336
Net Loss before other income and expenses
(28,692 ) (19,231 ) (53,532 ) (64,579 )
Interest expense
(630 ) (3,264 ) (9,525 ) (8,498 )
Net Loss
$ (29,322 ) $ (22,495 ) $ (63,057 ) $ (73,077 )
Loss per share - basic and diluted
$ (0.01 ) $ (0.00 ) $ (0.01 ) $ (0.01 )
Weighted average common shares
outstanding -  basic and diluted
4,990,000 4,990,000 4,990,000 4,990,000
The accompanying notes are an integral part of these unaudited financial statements
NAPROD IS , INC.
STATEMENT OF CASH FLOWS
(Unaudited)
For the nine months ended
May 31,
2013
2012
Operating Activities
Net loss
$ (63,057 ) $ (73,077 )
Adjustments to reconcile net loss to net cash used in operations:
Depreciation
10,305 10,203
Changes in operating assets and liabilities:
Accounts Receivable
(16,317 ) (14,229 )
Inventory
5,766 (2,469 )
Prepaid expenses
- (7,183 )
Accounts Payable and accrued expenses
63,472 15,176
Customer Deposits
7,335 1,629
Net Cash (used)/provided by operating activities
7,504 (69,950 )
Financiang Activities
Bank Overdraft
821
Net proceeds from officer loans
3,372 53,403
Net repayments to related party
(422 ) -
Net Cash provided by financing activities
2,950 54,224
Net Increase/(Decrease) in cash
10,454 (15,726 )
Cash, beginning of period
648 15,726
Cash, end of period
$ 11,102 $ -
Supplemental disclosures of cash flow information
Cash paid for
Interest
$ - $ -
Income taxes
$ - $ -
The accompanying notes are an integral part of these unaudited financial statements
NA PR ODIS, INC.
NOTES TO THE FINANCIAL STATEMENTS
(UNAUDITED)


NOTE 1 – BASIS OF PRESENTATION AND NA TURE OF BUSINESS
Nature of Business

Naprodis, Inc. (the “Company”) was incorporated in the state of Nevada on June 4, 1999. The Company is a pharmaceutical manufacturer, supplying natural raw materials and natural health care products to the health supplement and beauty product industry.  The Company also markets its own line of beauty products from its offices and laboratory in Poway, California.
Basis of Presentation
The financial statements presented include all adjustments which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the period presented in accordance with the accounting principles generally accepted in the United States of America. All adjustments are of a normal recurring nature
These unaudited interim financial statements as of and for the nine months ended May 31, 2013 reflect all adjustments which, in the opinion of management, are necessary to fairly state the Company’s financial position and the results of its operations for the periods presented, in accordance with the accounting principles generally accepted in the United States of America. All adjustments are of a normal recurring nature.
These unaudited interim financial statements should be read in conjunction with the Company’s financial statements and notes thereto included in the Company’s fiscal year end August 31, 2012 report on Form 10-K. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the nine month period ended May 31, 2013 are not necessarily indicative of results for the entire year ending August 31, 2013.
The financial statements of the comparative period ended May 31, 2012 have been recast on certain line items to comport with the presentation in the 2013 statements.
NOTE 2 – GOING CONCERN

As shown in the financial statements, the Company incurred a net loss of $(63,057) during the nine months ended May 31, 2013, and as of that date, the Company’s current liabilities exceeded its current assets by $386,990. The Company has accumulated a deficit of $(482,863). These factors create an uncertainty regarding the Company’s ability to continue as a going co concern.  The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
NOTE 3 – PAYABLES TO RELATED PARTIES

The Company has outstanding payables to companies that are related by common ownership are payable on demand and have no terms of repayment or maturity date. The payables bear interest ranging from 0-5%. The Company had net repayments of payables to related parties of $422 for the nine months ended May 31, 2013. The Company has an outstanding balance of $124,101 and $124,523 as of May 31, 2013, and August 31, 2012, respectively.


NOTE 4 – OFFICER LOANS

The Company has outstanding loans from the officers of the Company and has no terms of repayment or maturity, and are payable on demand and bear interest at 5% per annum. The Company had net proceeds from officer loans of $3,372 for the nine months ended May 31, 2013. The Company has an outstanding balance of $209,914 and $206,542 as of May 31, 2013, and August 31, 2012, respectively.


NOTE 5 – SEGMENT INFORMATION

Although the Company sells more than 400 products, only the Company’s skin care product line accounted for more than 10% of the Company’s revenue for the nine months ended May 31, 2013.  The following presents certain information concerning the nine month’s skin care product segment:
Nine months ended May 31, 2013
All Other
Skin Care
Segments
Total
Revenue
109,489
46,925
156,414
Segment profit (loss)
(16,989)
(46,068
)
(63,057
)
Segment assets (1)
19,200
93,117
112,317
Expenditures for Segment assets (1)
4,898
2,082
6,980

Nine months ended May 31, 2012
All Other
Skin Care
Segments
Total
Revenue
250,541
27,839
278,380
Segment profit (loss)
13,116
(52,980
)
39,834
Segment assets (1)
2,408
126,471
128,879
Expenditures for Segment assets
746
79
825

Three months ended May 31, 2013
All Other
Skin Care
Segments
Total
Revenue
25,899
12,014
37,913
Segment profit (loss)
(7,765)
(18,121
)
(25,886
)
Segment assets (1)
35,592
76,725
112,317
Expenditures for Segment assets (1)
1,148
0
1,148

Three months ended May 31, 2012
All Other
Skin Care
Segments
Total
Revenue
39,069
7,452
46,521
Segment profit (loss)
(1,048)
(14,534
)
(15,583)
Segment assets (1)
10,103
114,608
124,711
Expenditures for Segment assets
1,012
3,809
4,821
(1)
Inventory is the only asset that can be segmented since the remaining assets of the Company are used for all of the Company’s activities.
All other segments are:
* Body Care
* Hair Care
* Dietary Supplements
* Raw Materials which include:
* Essential Oils
* Hydrolates
* Clays
* Celtic Sea Salt
* Fatty Vegetal Oils
* Sea Algae

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties and are based on the beliefs and assumptions of management and information currently available to management. The use of words such as “believes”, “expects”, “anticipates”, “intends”, “plans”, “estimates”, “should”, “likely” or similar expressions, indicates a forward-looking statement.
The identification in this report of factors that may affect our future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty.
Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operation

General
The Company was incorporated in Nevada in June 1999.
Since September 2000 the Company has been in the business of selling dietary and personal care products.  The Company distributes its products primarily through private label resellers and through spas, beauty salons, health professionals, and health and beauty stores.  As of the date of this report the Company’s products were being sold in the United States and Canada along with several foreign countries.  The Company relies upon referrals from its customers and it website to market its products.
Material changes of certain items in the Company’s Statement of Operations for the three months ended May 31, 2013, as compared to the same period last year, are discussed below.

Increase (I)
Item
or Decrease (D)
Reason
Revenues
D
Loss of retail customers due to lack of sales force
Gross profit, as a percent of total revenue
D
Reduced product prices in an effort to increase sales
Material changes of certain items in the Company’s Statement of Operations for the nine months ended May 31, 2013, as compared to the same period last year, are discussed below.
Increase (I)
Item
or Decrease (D)
Reason
Revenues
D
Loss of retail customers due to lack of sales force
Gross profit, as a percentage of total revenue
D
Reduced product prices in effort to increase sales
Selling general and administrative expenses
D
reduction in expenses in response to loss of major customer
In October 2011, the Company’s largest customer, Plant Devas, which accounted for approximately 85% the Company’s its sales during the year ended August 31, 2011, decided to manufacture for its own account the products which they had previously been buying from the Company. The Company previously manufactured 22 products from its skin care segment for Plant Devas, who then resold the products under its own label.  The Company is now manufacturing these same 22 skin care products and selling them under its label.  The equipment used to manufacture the skin care products for Plant Devas was not custom built, but was the same equipment used, and which the Company is currently using, to manufacture all of its products.
Other than the foregoing, the Company does not know of any trends, events or uncertainties that have had, or are reasonably expected to have, a material impact on sales, revenues or income from continuing operations, or liquidity and capital resources.
Research and Development
During the past two years the Company research and development expenses have been less than $1,500.  However, the Company believes that in order to be competitive it will need to commit to continuous product innovation and improvement through research.  Research efforts will combine in-house research, published research, and clinical studies and will involve the following:

Investigation of the in vitro activity of new natural extracts,
Identification and research of combinations of nutrients that may be suitable for new products,
Analysis of the benefits of existing and newly identified nutritional supplements,
Improvement of existing products following new discoveries in nutrition, and
Improvements to manufacturing processes.
Item 4.  Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
An evaluation was carried out under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report on Form 10-Q.  Disclosure controls and procedures are procedures designed with the objective of ensuring that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, such as this Form 10-Q, is recorded, processed, summarized and reported, within the time period specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and is communicated to our management, including our Principal Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.  Based on that evaluation, our management concluded that, as of May 31, 2013, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended May 31, 2013, that materially affected or are reasonably likely to materially affect our internal control over financial reporting.
PART II

Item 6.  Exhibits

a.  Exhibits

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NAPRODIS, INC.
Date:  July 15, 2013
By:
/s/ Paul Petit
Paul Petit
President, Principal Executive,
Financial and Accounting Officer
8

TABLE OF CONTENTS